Albemarle Corporation (NYSE:ALB) EVP Matthew Juneau sold 5,397 shares of the firm’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $115.77, for a total value of $624,810.69. Following the completion of the transaction, the executive vice president now directly owns 360 shares of the company’s stock, valued at $41,677.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Albemarle Corporation (ALB) traded up 0.42% during mid-day trading on Monday, hitting $115.43. The stock had a trading volume of 594,732 shares. The firm’s 50-day moving average is $115.61 and its 200 day moving average is $108.13. Albemarle Corporation has a 12 month low of $75.11 and a 12 month high of $123.48. The company has a market cap of $12.75 billion, a price-to-earnings ratio of 14.76 and a beta of 1.59.

Albemarle Corporation (NYSE:ALB) last announced its earnings results on Monday, August 7th. The specialty chemicals company reported $1.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.02. Albemarle Corporation had a return on equity of 11.59% and a net margin of 31.49%. The company had revenue of $737.25 million during the quarter, compared to analyst estimates of $735.50 million. During the same period last year, the company posted $0.93 earnings per share. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. Equities analysts anticipate that Albemarle Corporation will post $4.36 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Investors of record on Friday, September 15th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.28 dividend on an annualized basis and a yield of 1.11%. Albemarle Corporation’s payout ratio is 16.41%.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/28/insider-selling-albemarle-corporation-alb-evp-sells-5397-shares-of-stock.html.

A number of hedge funds have recently made changes to their positions in ALB. Wells Fargo & Company MN raised its stake in shares of Albemarle Corporation by 16.5% in the first quarter. Wells Fargo & Company MN now owns 676,925 shares of the specialty chemicals company’s stock worth $71,511,000 after buying an additional 95,837 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD boosted its position in shares of Albemarle Corporation by 13.0% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 9,760 shares of the specialty chemicals company’s stock worth $1,031,000 after buying an additional 1,123 shares during the period. Conning Inc. bought a new position in shares of Albemarle Corporation during the first quarter worth about $205,000. IFP Advisors Inc boosted its position in shares of Albemarle Corporation by 12.6% in the first quarter. IFP Advisors Inc now owns 5,000 shares of the specialty chemicals company’s stock worth $528,000 after buying an additional 559 shares during the period. Finally, Janney Montgomery Scott LLC boosted its position in shares of Albemarle Corporation by 7.0% in the first quarter. Janney Montgomery Scott LLC now owns 3,546 shares of the specialty chemicals company’s stock worth $375,000 after buying an additional 232 shares during the period. Hedge funds and other institutional investors own 84.00% of the company’s stock.

Several research analysts have issued reports on ALB shares. Zacks Investment Research lowered Albemarle Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Oppenheimer Holdings, Inc. started coverage on Albemarle Corporation in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $133.00 target price for the company. Aegis restated a “buy” rating on shares of Albemarle Corporation in a research note on Friday, July 7th. Royal Bank Of Canada restated a “buy” rating and issued a $136.00 target price on shares of Albemarle Corporation in a research note on Friday, July 14th. Finally, Jefferies Group LLC set a $144.00 price target on Albemarle Corporation and gave the company a “buy” rating in a report on Monday, August 21st. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $110.94.

Albemarle Corporation Company Profile

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Insider Buying and Selling by Quarter for Albemarle Corporation (NYSE:ALB)

Receive News & Stock Ratings for Albemarle Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Corporation and related stocks with our FREE daily email newsletter.